Actively Recruiting
Membrane Target Detection for Leukemia Treatment
Led by University of Missouri-Columbia · Updated on 2025-12-10
50
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. We also found DPP4 is highly expressed in other hematological malignancies in our mouse model, thus we would like to use human samples to investigate the role of DPP4 in hematological malignancy development and the mechanism underlying, especially to deeply understand the role of DDP4 in leukemia.
CONDITIONS
Official Title
Membrane Target Detection for Leukemia Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of any hematological malignancy
- Must be 18 years or older
You will not qualify if you...
- Impaired decision-making abilities
- Pregnant women or fetuses
- Children under 18 years old
- Non-viable newborns or newborns of uncertain viability
- Non-English speaking individuals
- Prisoners
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Missouri
Columbia, Missouri, United States, 65212
Actively Recruiting
Research Team
X
Xunlei Kang, MD.PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here